GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Upon further reflection, I feel these milestones may be quite large. I've assumed already here that the "middle-ground" for negotiations is huge milestones with sub-optimal royalties and little upfront cash.<

The fourth variable is funding of the clinical program in DIC—and, eventually, other acquired indications.

If GTC and Leo run a unified phase-3 DIC program for the world excluding Japan (#msg-24872298), Leo will presumably fund about half the cost. This leaves the funding of the other half as one of the key terms in the US partnership deal.